Next Science Limited (NXSCF)

Market Cap	28.30M +21.6%
Revenue (ttm)	22.07M -5.3%
Net Income	-9.43M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,000
Average Volume	15,578
Open	0.0160
Previous Close	0.0150
Day's Range	0.0160 - 0.0160
52-Week Range	0.0002 - 0.1133
Beta	1.22
RSI	38.63
Earnings Date	Feb 26, 2026

About Next Science

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: NXSCF

Financial Performance

In 2024, Next Science's revenue was $22.82 million, an increase of 2.87% compared to the previous year's $22.18 million. Losses were -$10.59 million, -34.94% less than in 2023.